Nxera Pharma Co., Ltd. Third Quarter Financial Summary [IFRS] (Consolidated)

Performance Overview

Nxera Pharma Co., Ltd. recorded revenue of 27,742 million yen for the cumulative third quarter period, with core operating profit of 9,818 million yen, operating profit of 3,175 million yen, and quarterly profit of 2,328 million yen. The company has turned from a large loss in the same quarter of the prior year to profitability. By product, sales of Pivratz® and Cubivic® remained solid, while revenue in the respiratory disease segment declined. R&D expenses decreased, and certain costs were reassessed, with structural reform expenses recorded. Full-year guidance is revenue of 33,800–48,800 million yen, core operating profit of 7,800–22,800 million yen, and operating profit of 700–15,700 million yen.

Outlook and Impact for Investors

Important license agreements and milestone income are expected to continue, and the company will continue to promote partnerships and in-house development leveraging the NxWave platform. From 2026 onward, the company aims to expand new partnerships and advance program phases; while monitoring factors such as foreign exchange and impairments, recognition of multiple milestone incomes could contribute to results. Although cash and cash equivalents are trending downward, improvement in cash generation is expected through portfolio expansion and partnership outcomes.